Somatuline Predictive Factors in Acromegaly and NET

Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel® (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)

The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.

Inclusion Criteria:

• Written informed consent (also mandatory in case of retrospective documentation of subject data)
• Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on treatment with ATG

Exclusion Criteria:

• The subject has already been included in this study
• Participation in an interventional trial